Robeco Institutional Asset Management
RPRX icon

Robeco Institutional Asset Management’s Royalty Pharma RPRX Stock Holding History

Robeco Institutional Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.1M Sell
911,586
-33,008
-3% -$1.72M 0.06% 264
2026
Q1 		$45.3M Sell
944,594
-4,878
-0.5% -$214K 0.06% 260
2025
Q4 		$36.7M Sell
949,472
-299,147
-24% -$11.4M 0.05% 280
2025
Q3 		$44.1M Buy
1,248,619
+474,459
+61% +$17.2M 0.06% 248
2025
Q2 		$27.9M Buy
774,160
+147,112
+23% +$4.87M 0.05% 305
2025
Q1 		$19.5M Buy
627,048
+78,287
+14% +$2.48M 0.04% 337
2024
Q4 		$14M Buy
548,761
+43,926
+9% +$1.16M 0.03% 384
2024
Q3 		$14.3M Buy
504,835
+165,440
+49% +$4.58M 0.03% 386
2024
Q2 		$8.95M Buy
339,395
+264,900
+356% +$7.34M 0.02% 442
2024
Q1 		$2.26M Buy
74,495
+24,043
+48% +$709K ﹤0.01% 660
2023
Q4 		$1.42M Buy
50,452
+42,256
+516% +$1.16M ﹤0.01% 748
2023
Q3 		$222K Sell
8,196
-966
-11% -$28.7K ﹤0.01% 915
2023
Q2 		$282K Sell
9,162
-14,399
-61% -$488K ﹤0.01% 912
2023
Q1 		$849K Sell
23,561
-30,867
-57% -$1.14M ﹤0.01% 796
2022
Q4 		$2.15M Sell
54,428
-51,675
-49% -$2.16M 0.01% 688
2022
Q3 		$4.26M Buy
106,103
+30,450
+40% +$1.3M 0.01% 539
2022
Q2 		$3.18M Buy
75,653
+43,027
+132% +$1.76M 0.01% 585
2022
Q1 		$1.27M Buy
32,626
+27,347
+518% +$1.07M ﹤0.01% 687
2021
Q4 		$210K Hold
5,279
– – ﹤0.01% 839
2021
Q3 		$191K Hold
5,279
– – ﹤0.01% 852
2021
Q2 		$216K Hold
5,279
– – ﹤0.01% 876
2021
Q1 		$231K Buy
+5,279
New +$250K ﹤0.01% 860

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Robeco Institutional Asset Management's RPRX Position: Q2 2026 in Review

Robeco Institutional Asset Management reduced its Royalty Pharma (RPRX) stake by 3.5% in Q2 2026, selling an estimated $1.72M and leaving 911,586 shares worth $51.1M. The position accounts for 0.06% of the portfolio, ranked #264.

Robeco Institutional Asset Management first reported a position in RPRX in Q1 2021 and has held it in 22 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Robeco Institutional Asset Management held 911,586 shares of Royalty Pharma worth $51.1M as of Q2 2026.
  • Robeco Institutional Asset Management sold 33,008 Royalty Pharma shares in Q2 2026, an estimated $1.72M.
  • Royalty Pharma made up 0.06% of Robeco Institutional Asset Management's portfolio in Q2 2026, its #264 holding.
  • Robeco Institutional Asset Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 22 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Robeco Institutional Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.